Blog
RSS FeedPosted by Michael Wonder on 18 Oct 2021
Alnylam receives positive reimbursement recommendation from the CADTH for use of Givlaari for the treatment of acute hepatic porphyria in adults
18 October 2021 - Givlaari reduces chronic pain, improves quality of life and is the first and only therapy proven ...
Posted by Michael Wonder on 30 Aug 2021
Evrysdi (risdiplam) receives CADTH reimbursement recommendation for some patients with spinal muscular atrophy
30 August 2021 - Roche Canada today announced that the CADTH Canadian Drug Expert Committee has issued its final recommendation ...
Posted by Michael Wonder on 22 Jul 2021
Dupixent (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
22 July 2021 - Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, ...
Posted by Michael Wonder on 04 Mar 2021
Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases
4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive ...
Posted by Michael Wonder on 10 Nov 2020
Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug
10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 01 Nov 2020
CADTH recommends new treatment option for patients with plaque psoriasis
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 22 Oct 2020
Nexplanon recommended after second submission
22 October 2020 - The first submission was withdrawn. ...
Posted by Michael Wonder on 22 Oct 2020
CADTH in favour of new indication for Soliris
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...
Posted by Michael Wonder on 06 Oct 2020
Next-generation wet AMD therapy Beovu, now available in Canada, receives positive recommendation from CADTH Drug Expert Committee
5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu. ...
Posted by Michael Wonder on 01 Sep 2020
CADTH publishes final outcome for new medicine for patients with acquired thrombotic thrombocytopenic purpura
1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of ...
Posted by Michael Wonder on 24 Aug 2020
CADTH publishes final recommendation on new indication for Soliris
24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder. ...
Posted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...
Posted by Michael Wonder on 27 Jul 2020
CADTH posts final recommendation for Aimovig
26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...
Posted by Michael Wonder on 23 Jul 2020
CADTH publishes final recommendation for Mayzent
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...